Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2012

View Archived Issues

Chugai recaps development activities of third quarter 2012

First-in-class protein kinase inhibitor evaluated in Japanese patients with solid tumors

Phase I trial results reported for novel vaccine for glioblastoma

Cellectis obtains exclusive license for genome engineering tools

Shire and Fondazione Telethon enter research collaboration for rare diseases

ALX-009 reduces P. aeruginosa biofilm formation

Data presented from phase II study of pazopanib in NETs

Data for phase II TemAvir study in patients with glioblastoma presented

Elara Pharmaceuticals discloses novel HIF-1-alpha inhibitors

Atlanthera discloses new agents for cancer and other disorders

IMPACT Therapeutics patents new PARP-1 inhibitors

Japanese group patents novel anticancer CDC7 inhibitors

New double-stranded RNA molecules disclosed for the treatment of cancer

ADX-71441 shows promise in preclinical model of alcohol binge drinking

Teijin Pharma to begin phase I/II trial of KTP-001

ViaCyte receives grant to continue development of diabetes therapy

Salivary miRNAs identified as potential noninvasive diagnostic method in esophageal cancer

Shionogi and ViiV Healthcare form new integrase inhibitor agreement

E.U. approval for linagliptin as add-on therapy in type 2 diabetes

Phase III enobosarm trial to continue after planned safety review

Evotec extends Huntington's disease collaboration

Isis begins phase II study of ISIS-FXIRx in knee replacement surgery

Novel TNFR-Fc fusion protein shows promise in animal models of Alzheimer's disease

Application for additional approval for Lucentis filed in Japan

Second-generation aminoglycoside derivative leads dose-dependent rescue of CFTR currents in vitro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...